A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: HIV -1 Infection
In brief
This study will test the safety and blood levels of the antibody BNT351 in people living without and with human immunodeficiency virus (HIV). This study will also test the anti-viral activity of BNT351 in people living with HIV (PLWH) with detectable virus levels. The main goals of this study are: * To learn about the safety of BNT351 and check for side effects. * To measure the amount of BNT351 antibody in blood over time. * To test the amount of HIV in the blood at different times after treatment with BNT351 in people living with HIV.
Key facts
- Study ID
- NCT07392372
- Run by
- BioNTech SE
- People needed
- 67
- Starts
- 2026-02-09
- Expected to finish
- 2027-06-01
- Last updated by the study team
- 2026-06-22
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Johns Hopkins — Baltimore, Maryland, United States (enrolling)
- UK Köln — Cologne, Germany (enrolling)
- Cook County Health — Chicago, Illinois, United States
- Washington University — St Louis, Missouri, United States
- Columbia University — New York, New York, United States
- CRS Mannheim — Mannheim, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.